Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences

PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease

Tuo Shao, Steven Liang and Jian Rong
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 4122;
Tuo Shao
1Massachusetts General Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Liang
2Harvard Medical School and Mass General Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Rong
3Emory University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

4122

Introduction: Neuroinflammation is a fundamental underlying hallmark of Alzheimer’s disease (AD), a debilitating neurodegenerative condition marked by accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles composed of aggregated amyloid β (Aβ) and hyperphosphorylated tau, respectively, leading to progressive cognitive impairment and dementia. Monoacylglycerol lipase (MAGL) is an enzyme belonging to the serine hydrolase superfamily metabolizing lipids, but its most striking role unveiled within this decade is in hydrolyzing the endogenous cannabinoid 2-arachidonoylglycerol (2-AG), resulting in the release of the free fatty acid arachidonic acid (AA), a precursor of eicosanoids, and glycerol. This is evidenced by the observations where inhibition of MAGL by a selective and potent inhibitor JZL184 dramatically elevates brain levels of 2-AG and decreases levels of AA and AA-derived prostaglandins, suggesting that MAGL is a promising therapeutic target for preventing and treating AD. Here we show that MAGL inhibition prevents and decreases synthesis and accumulation of Aβ and suppresses microglial and astrocytic activation and prevents neurodegeneration; and [18F]MAGL-2102 PET enabled imaging MAGL changes after JZL184 treatment in these.

Methods: We employed 5XFAD transgenic (TG) mice as AD model; JZL184 was dissolved in the vehicle containing Tween-80 (10%), DMSO (10%) and saline (80%). We treated TG mice with vehicle or JZL184 (12 mg/kg) three times per week by intraperitoneal (i.p.) starting at 2 months of age for 16 weeks or starting at 4 months of age for 8 weeks. Western blot assay was conducted to determine production of MAGL and expression of APP in the brain from WT and TG mice treated with vehicle or JZL184. Immunohistochemical analyses were performed to determine astrocytic (GFAP) and microglial (Iba-1) markers in coronal sectioned brain slices. We used an MAGL-specific PET to evaluate cerebral MAGL PET signal and uptake in the 5XFAD mouse models.

Results: We found that JZL184 reduced reactive astrocytic and microglial cells in the hippocampus of TG mice (Fig. 1), indicating that neuroinflammation was suppressed when MAGL is inhibited. Figure 2 represents summed transverse, coronal and sagittal cerebral PET/CT images (0-60 min) of normal WT mice, 5XFAD mice, WT + JZL184 mice and 5XFAD+ JZL184. The tracer uptake was gradually declined after JZL184 treatment in WT mice. Declined uptakes of [18F]MAGL-2102 were also found in 5XFAD mice+JZL184 compared with 5XFAD. Significantly lower levels of radioactivity were observed in WT+JZL184 and 5XFAD+JZL184. Time-activity curves (TACs) were analyzed by drawn interest area for [18F]MAGL-2102 in the brain between 0- and 60-min. TACs which radioactivity is expressed as %injected dose per gram (%ID/g). Brain APP was detected in TG mice. As shown in Figure 3 and figure 4, MAGL inhibition for 16 weeks robustly decreased total MAGL and APP in the hippocampus.

Conclusions: [18F]MAGL-2102 is a promising candidate for noninvasive imaging of target engagement of MAGL therapeutics for Alzheimer’s disease.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease
Tuo Shao, Steven Liang, Jian Rong
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4122;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease
Tuo Shao, Steven Liang, Jian Rong
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4122;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences

  • PET CT Quantification to direct Alzheimer’s patients to anti-amyloid therapy
  • Multicenter trial study for usefulness of physical parameters toward the standardization of brain SPECT image: relation to visual analysis
  • Assessment of Brain Perfusion 123I-IMP SPECT imaging Using Low Energy High Resolution Collimator image reconstructed by Flash 3D
Show more Neurosciences

PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease

  • PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease
Show more PET quantifies target engagement of MAGL therapeutics for Alzheimer’s disease

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire